Nuveen Asset Management, LLC T Scan Therapeutics, Inc. Transaction History
Nuveen Asset Management, LLC
- $340 Billion
- Q4 2024
A detailed history of Nuveen Asset Management, LLC transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 69,962 shares of TCRX stock, worth $154,616. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,962
Previous 69,962
-0.0%
Holding current value
$154,616
Previous $348,000
39.37%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding TCRX
# of Institutions
80Shares Held
37.8MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.86MShares$17.4 Million3.37% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$11.5 Million0.3% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$9.86 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$6.15 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$4.75 Million0.0% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $41.8M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...